Aphton Announces Presentation at UBS Global Life Sciences Conference
Posted on: Tuesday, 20 September 2005, 09:00 CDT
Aphton Corporation (NASDAQ:APHT), a biotechnology company focused on the development of immunotherapies for the treatment of cancer, announced today that Patrick Mooney, M.D., Chairman and CEO, will present an overview of the company at the upcoming UBS Global Life Sciences Conference to be held at the Grand Hyatt in New York City.
Dr. Mooney's presentation will be on Tuesday, September 27th at 3:30 p.m. EDT. A live audio webcast of the presentation can be accessed by visiting the UBS conference website at www.ibb.ubs.com. A replay of the presentation will begin 3 hours after the actual presentation and will be available until October 29, 2005.
About Aphton
Aphton Corporation, headquartered in Philadelphia, Pennsylvania is a clinical stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Aphton's products seek to empower the body's own immune system to fight disease. Through the acquisition of Igeneon AG in March 2005, Aphton acquired late-stage products, IGN101, a cancer vaccine designed to induce an immune response against EpCAM positive tumor cells, and IGN311, a fully humanized antibody against the Lewis Y antigen. Aphton has strategic alliances with Xoma for treating gastrointestinal and other gastrin-sensitive cancers using anti-gastrin monoclonal and other antibodies; Daiichi Pure Chemicals for the development, manufacturing and commercialization of gastrin-related diagnostic kits; and sanofi-aventis for the development and commercialization of Insegia (G17DT immunogen) related to cancers of the gastrointestinal system and other cancers in North America and Europe. Aphton is also currently seeking other partners that will support the further development of Insegia. For more information about Aphton or its programs please visit Aphton's website at www.aphton.com.
Source: Business Wire
Related Articles
- Ortho Biotech Oncology Research & Development Announces Collaboration with National Cancer Institute to Develop Novel Cell Therapies to Treat Cancer
- Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
- Statement of the American Cancer Society Cancer Action Network, American Heart Association, American Lung Association and the Campaign for Tobacco-Free Kids
- Bionovo Announces Presentation at the National Cancer Institute
- Curis Selects First Development Candidate From Its Targeted Cancer Drug Development Platform
- Defibrotide Mechanism of Action Data to Be Presented at Mechanisms Linking Cancer and Inflammation Symposium
- Statement of the American Cancer Society Cancer Action Network(Sm)and Campaign for Tobacco-Free Kids on D.C. Councilmember Orange'sSupport of Comprehensive Smoke-Free Workplace Bill
- Epigenomics AG to Present Data From Breast Cancer Outcome Prediction Study
- Developed Countries Still Carry Greatest Cancer Burden
 |
 |
User Comments (0)
RSS Feeds